Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Drugs Aim To Move Needle In Tough-to-Treat Acute Myeloid Leukemia

Executive Summary

Response rates for candidates from Stemline, Seattle Genetics and Karyopharm look highly encouraging, but the real test in AML will be survival, as the field is still in the shadow of Pfizer's failed Mylotarg.

You may also be interested in...



Novartis' Rydapt: Two Indications, Two Prices

Rydapt was approved by the US FDA for the one-third of patients with acute myeloid leukemia who test positive for a FLT3 mutation, which is associated with a poorer prognosis, and for advanced systemic mastocytosis.

Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers

Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC097789

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel